2 recruiting, 2 unknown, 1 not yet recruiting. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Unknown 2 |
| Phase 2 | 4 | Unknown 2, Not yet recruiting 1, Recruiting 1 |
Follow Zhejiang Yangli Pharmaceutical Technology Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension VB19055 Dose A QD, VB19055 Dose B QD, VB19055 Dose C QD - Hypertension, Resistant Hypertension | Phase 2 | Not yet recruiting | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | 240 | 2026-09-01 | 2026-09-22 |
| VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population VB19055, VB19055 placebo - Hypertension | Phase 1 | Recruiting | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | 86 | 2025-10-05 | 2025-11-28 |
| Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors VB15010 - Cancer, Neoplasms | Phase 1 / Phase 2 | Recruiting | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | 188 | 2024-10-30 | 2025-02-11 |
| Study of TFX06 in Women With Advanced Breast Cancer. TFX06 tablet - ER+, HER2- Advanced Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Unknown | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | 74 | 2023-04-17 | 2023-07-03 |
| A Study of TFX05-01 in Patients With Advanced Solid Tumors TFX05-01 - Advanced Solid Tumor | Phase 1 / Phase 2 | Unknown | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | 36 | 2022-06-05 | 2023-03-16 |
Breast Neoplasms (2) · Hypertension (2) · Biliary Tract Neoplasms (1) · Colorectal Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
China (5)
Jiguang Wang (2) · Jian Zhang (1) · Yuankai Shi (1)